Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Regenerative Therapies For Osteoarthritis Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The regenerative therapies for osteoarthritis market size has seen rapid growth in recent years. It is anticipated to increase from $3.04 billion in 2025 to $3.46 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.9%. The expansion observed historically can be attributed to the rising prevalence of osteoarthritis, the growth of the aging population, the limitations associated with pain relief drugs, an increase in sports injuries, and a demand for non-surgical treatment options.
The market for regenerative therapies for osteoarthritis is anticipated to experience swift expansion over the coming years. It is projected to reach $5.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period can be attributed to factors such as increased biologic therapy adoption, the expansion of regenerative clinics, growing clinical evidence support, a rising demand for cartilage restoration, and higher investment in cell therapy research. Key trends expected in the forecast period encompass stem cell-based joint repair therapies, platelet-rich plasma treatment protocols, scaffold-based cartilage regeneration, minimally invasive regenerative injections, and personalized biologic therapy plans.
Get A Free Sample Report With In-Depth Market Insights:
Regenerative Therapies For Osteoarthritis Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The regenerative therapies for the osteoarthritis market is anticipated to grow due to the increasing prevalence of musculoskeletal disorders. These disorders are conditions that affect bones, joints, muscles, and connective tissues, leading to pain and limitations in mobility and dexterity. The rising occurrence of musculoskeletal disorders is largely fueled by an aging population, as older individuals often experience higher rates of joint degeneration and inflammatory conditions impacting musculoskeletal structures. Consequently, the increasing incidence of musculoskeletal disorders drives demand for regenerative therapies, which offer advanced treatment options for joint restoration and tissue repair in osteoarthritis patients. For instance, according to the Office for Health Improvement & Disparities, a UK-based government agency, in January 2024, it was reported that 18.4% of individuals aged 16 and above in 2023 had a long-term musculoskeletal (MSK) condition, an increase from 17.6% in 2022. Therefore, the expanding prevalence of musculoskeletal disorders is a significant factor propelling the growth of the regenerative therapies for the osteoarthritis market.
Regenerative Therapies For Osteoarthritis Market Segmentation: How Does The Market Break Down By Category?
The regenerative therapies for osteoarthritis market covered in this report is segmented –
1) By Therapy Type: Stem Cell Therapy; Platelet Rich Plasma Therapy; Tissue Engineering; Gene Therapy; Other Therapy Types
2) By Distribution Channel: Direct Manufacturer Supply; Hospital And Clinic Procurement Channels; Specialty Medical Distributors
3) By Application: Knee Osteoarthritis; Hip Osteoarthritis; Hand Osteoarthritis; Other Applications
4) By End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End Users
Subsegments:
1) By Stem Cell Therapy: Autologous Stem Cell Therapy; Allogeneic Stem Cell Therapy; Mesenchymal Stem Cell Therapy; Adipose Derived Stem Cell Therapy; Bone Marrow Derived Stem Cell Therapy
2) By Platelet Rich Plasma Therapy: Leukocyte Rich Platelet Rich Plasma Therapy; Leukocyte Poor Platelet Rich Plasma Therapy; Activated Platelet Rich Plasma Therapy; Non Activated Platelet Rich Plasma Therapy; Pure Platelet Rich Plasma Therapy
3) By Tissue Engineering: Scaffold Based Tissue Engineering; Hydrogel Based Tissue Engineering; Biodegradable Matrix Tissue Engineering; Cell Seeded Tissue Engineering; Three Dimensional Tissue Engineering
4) By Gene Therapy: Viral Vector Gene Therapy; Non Viral Vector Gene Therapy; In Vivo Gene Therapy; Ex Vivo Gene Therapy; Targeted Gene Therapy
5) By Other Therapy Types: Hyaluronic Acid Therapy; Growth Factor Therapy; Chondrocyte Implantation Therapy; Peptide Based Therapy; Immunomodulatory Therapy
Regenerative Therapies For Osteoarthritis Market Innovation Trends Shaping Future Development
Leading companies in the regenerative therapies for the osteoarthritis market are concentrating on developing advanced solutions, such as allogeneic mesenchymal stem cell (MSC) osteoarthritis therapies, to address the increasing demand for disease-modifying treatments. These allogeneic mesenchymal stem cell (MSC) osteoarthritis therapies utilize donor-sourced stem cells to regulate inflammation and aid cartilage regeneration in affected joints, offering a ready-to-use and scalable option compared to patient-derived cells, thereby enabling standardized dosages and broader adoption. For instance, in December 2025, Cipla Limited, an India-based pharmaceutical company, collaborated with Stempeutics Research, an India-based research and product development company, to introduce Ciplostem, a novel allogeneic MSC treatment specifically for knee osteoarthritis. This therapy is administered as a single intra-articular injection containing 25 million cultured adult human bone marrow-derived MSCs co-formulated with hyaluronic acid. It is designed to act at the cellular level to diminish inflammation, impede disease progression, enhance joint function, and assist in preserving cartilage quality for patients with Grade II and III knee OA. The main characteristics of this therapy include its off-the-shelf availability (eliminating the need for individualized preparation), its cellular-level mechanism of action contrasting with mere symptomatic relief, and its potential for sustained improvement in joint health when compared to standard regimens.
Regenerative Therapies For Osteoarthritis Market Competitive Overview And Top Companies
Major companies operating in the regenerative therapies for osteoarthritis market are Stryker Corporation, Smith & Nephew plc, MiMedx Group Inc, Anika Therapeutics Inc, Regentis Biomaterials Ltd, Zomedica Corp, Biosplice Therapeutics Inc, Tissue Regenix Group plc, Co.don AG, MEDIPOST Co Ltd, Ampio Pharmaceuticals Inc, Kolon TissueGene Inc, Mesoblast Limited, Orgenesis Inc, Hyalex Orthopaedics Limited, Orthocell Limited, Jellagen Limited, Hyalogic LLC, Bionaut Labs Inc, and Regeneus Limited.
View The Full Regenerative Therapies For Osteoarthritis Market Report:
Regenerative Therapies For Osteoarthritis Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the regenerative therapies for osteoarthritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the regenerative therapies for osteoarthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model